摘要
目的探讨利培酮联合艾司西酞普兰治疗慢性精神分裂症阴性症状的临床疗效以及安全性。方法将80例以阴性症状为主的慢性精神分裂症患者随机分为合用组和单用组,疗程12周,采用阳性和阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和安全性。结果合用组显效率77.5%,单用组显效率55%。治疗后两组PASS评分均较治疗前有显著性下降,差异有统计学意义(P<0.01)。治疗后2、4、8、12周末,合用组阴性因子分较单用组明显下降,差异有统计学意义(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论利培酮联合艾司西酞普兰治疗慢性精神分裂症阴性症状起效快、疗效好,不良反应少。
Objective To evaluate clinical efficacy and safety of escitalopram combined with risperidone in the treatment of negative symptoms of chronic schizophrenia paitents.MethodsDivided 80 patients with predominantly negative symptoms of chronic schizophrenia into combined group（escitalopram combined risperdone） and control group（risperidone alone） with 12 weeks treatment. PANSS and TESS were used to assess the efficacy and safety respectively.ResultsThe significant improvement rate in combined group was higher（77.5% ） than control group（55%）, compared with before treatment, PANSS scores decreased significantly after treatment（P〈0.01）. After 4 weeks treatment, the total scores and negative symptoms scores of PANSS significantly decreasaed in combined group compared to control group（P〈0.05） There were no significant differences in side effects between two groups. ConclusionEscitalopram combined with risperidone in the treatment of chronic schizophrenia with negative symptoms show rapid response, better efficacy and good patient compliance.
出处
《中国实用医药》
2014年第19期33-34,共2页
China Practical Medicine
